Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Novo Nordisk has the market’s top-selling obesity drug in Wegovy, a product whose main ingredient is a peptide engineered to mimic the hormone that activates the GLP-1 receptor. R&D efforts ...

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance ...

NovoCare Pharmacy is a direct-to-patient service that offers various dosages of Wegovy. Patients can purchase a month’s supply for a $499 cash payment. Originally, this reduced price was only ...

Novo Nordisk ... of Novo Nordisk's blockbuster diabetes injection Ozempic, which is taken once a week. Both treatments, as well as the company's weekly weight loss injection Wegovy, contain ...